Despite the current regulatory uncertainty, pharmaceutical companies should move forward with planning for serialization and pedigree.
Companies need to avoid operating in a manner that is inconsistent with the priorities established in the strategic sourcing decision.
The supply chain can be used as a tool for managing not only product supply risks, but overall business risks as well.
Many CMO relationships are established while a product is early in clinical or preclinical development.